Onward Medical N.v. · EURONEXT:ONWD
Onward Medical — Q3 2024 Earnings Presentation
27 slides from Onward Medical's earnings presentation, Nov 26, 2024
Slide 1: Investor Webcast Q3 2024 Business Update
Investor Webcast Q3 2024 Business Update November 26, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation may include statements, including the Company’s financial and operational medium-term objectives, that may be deemed to be ‘’forward-looking statements''. These forward-looking statements may be identified by the use of forward-looking terminology, includ
Slide 3: Speaking Today
Speaking Today Dave Marver Jocelyne Bloch, MD CEO Neurosurgeon, Co-founder and Medical Advisor Amori Fraser Finance Grégoire Courtine, PhD Director Neuroscientist, Co-founder and Scientific Advisor November 2024 Webcast 3
Slide 4: Introduction
Introduction November 2024 Webcast 4
Slide 5: ONWARD Medical at a Glance
ONWARD® Medical at a Glance Key Facts o Founded in 2015 Technology: 3 purpose-built neuromodulation platforms o ARCEX® delivers ARC Therapy externally through the skin o ~100 FTEs o ARCIM® delivers ARC Therapy via a fully implanted system o HQ in the Netherlands o ARCBCI pairs ARCIM with an implante
Slide 6: Vision
Vision Empowered by independence, people with spinal cord injury will enjoy life in the ways that matter to them November 2024 Webcast 6
Slide 7: Our Technology
Targeted, programmed electrical stimulation of the spinal Our Technology cord to restore movement, function, and independence in people with spinal cord injury Note: Investigational devices, not available for commercial use. November 2024 Webcast 7
Slide 8: Company Focus
Reach commercial stage by year-end, then expand labeling and platforms Company Focus Short Term 2024 Medium Term Long Term 2026/2027 2026/2027+ Commercialize external platform (ARCEX) Commercialize implantable platform (ARCIM) Expand labeling and platforms First indication: Upper Limb First indicati
Slide 9: Current Pipeline
9 indications under clinical or pre-clinical evaluation, with 3 in current roadmap Current Pipeline Short and medium term focus Funded primarily through grants and research partners Clinical Platform Indication FDA BDD1 Pre-clinical Human PoC Pivotal Feasibility2 ARCEX Upper Limb Study expected to s
Slide 10: Q3 2024 Update
Q3 2024 Update November 2024 Webcast 10
Slide 11: Q3 Business Update
Achievements since July include in-licensing BCI system, raising €50M and being awarded 2024 TIME Q3 Business Update Magazine Best Invention July July September September September Science Corporate Clinical Clinical Corporate Announced publication Announced publication Awarded Christopher & Announc
Slide 12: BCI License Agreement
Secured exclusive rights to CEA’s WIMAGINE BCI technology BCI License Agreement ” CEA’s Clinatec is a world-renowned biomedical research institute and its BCI is ideal for our applications. We can now develop a truly integrated system that is well suited for the type of study required to gain regula
Slide 13: BCI Selection and Potential Impact
BCI Selection and Potential Impact Jocelyne Bloch, MD G Courtine, PhD Neuroscientist, Co-founder and Neurosurgeon, Co-founder and Scientific Advisor Medical Advisor November 2024 Webcast 13
Slide 14: In-House BCI Value Add
Exclusive rights to CEA’s WIMAGINE BCI technology provides several opportunities In-House BCI Value Add License agreement signed with CEA for the WIMAGINE BCI system provides ONWARD Medical with the opportunity to: o Be first to market with a BCI-enabled system to restore thought-driven movement aft
Slide 15: Board Changes
Welcomed incoming Chairman of the Board Rob ten Hoedt and Rahma Samow Board Changes Rob ten Hoedt o Former Medtronic President and Executive Committee Member o Over 30 years of experience in medical devices o Successful track record in technology development, commercialization, and business-model in
Slide 16: October 2024 Capital Raise
Upsized capital increase with cornerstone investment from Ottobock October 2024 Capital Raise o €50M raised in upsized capital increase o Strategic investment from Ottobock, a global leader in prosthetics, orthotics and exoskeleton technology: - Now the company’s largest shareholder (~10% of ONWARD
Slide 17: Strategic Investment
Strategic investment from Ottobock, with opportunities for future collaboration Strategic Investment ” ONWARD Medical has the potential to o Over 100 years serving people with movement become a gamechanger in the therapy of disabilities; global leader in prosthetics, orthotics and spinal cord injuri
Slide 18: ARCEX Recognition
Named one of TIME’s Best Inventions of 2024 ARCEX Recognition ” ‘For most people with a spinal cord injury, there’s some [brain signal] conduction making it through the block, but not enough for movement,’ says Dave Marver, CEO of ONWARD. ‘This device serves as an amplifier.’ TIME Magazine The Best
Slide 19: Financial Update
Financial Update November 2024 Webcast 19
Slide 20: Q3 2024 Cash Update
With addition of proceeds from October 2024 Q3 2024 Cash Update capital raise, current cash position expected to fuel operations for two years or more Burn Q3 Ending Balance Current Ending Balance €8.9M used during Q3 €23.2M net cash2 as of €65.8M net cash2 as of 2024 30 Sep 2024 22 Nov 2024 (includ
Slide 21: Outlook
Outlook November 2024 Webcast 21
Slide 22: Upcoming Milestones and News Flow
Several important catalysts expected in the next 12 months Upcoming Milestones and News Flow ARCEX ARCEX ARCEX ARCEX FDA clearance First commercial sale (US) MDR submission CE mark Upper limb Upper limb Upper limb Upper limb ARCIM ARCIM ARCEX ARCIM First participant enrollment1 Early IDE submission
Slide 23: Q&A
Q&A November 2024 Webcast 23
Slide 24: Thank you!
Thank you! November 2024 Webcast 24
Slide 25: Slide 25
Slide 26: Appendix
Appendix November 2024 Webcast 26
Slide 27: BCI Selection Considerations
CEA’s WIMAGINE BCI enables our imperative to be first-to-market with BCI-augmented BCI Selection movement restoration Considerations Other BCI technologies Safety CEA’s WIMAGINE system is cleared for human research with A limited number of other BCI platforms cleared for investigation in ~7 years of